ERBB2 and breast cancer: Furthermore, resistance to targeted therapies in HER-2 amplified breast cancer can be conferred by microRNA-4728-mediated suppression of NOXA which serves to prevent apoptosis of breast cancer cells in an MCL-1 dependent manner [36].